))
LARVOL Onco Data Podcast with Dr. Amol Akhade & Dr. Guru Sonpavde | Post-ESMO | E.32
Manage episode 444078348 series 3606267
Bruno Larvol, Mark Gramling, Bruno Larvol, and Mark Gramling द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Bruno Larvol, Mark Gramling, Bruno Larvol, and Mark Gramling या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।
In this engaging episode of the LARVOL Onco Data Podcast, Guru Sonpavde, MD, and Dr. Amol Akhade delve into key takeaways from the latest oncology discussions at ESMO24. The conversation highlights the expanding treatment options for physicians. Our VP of Oncology, Dr. Mark Gramling, emphasized the importance of focusing on the optimal sequencing of treatments like Ambassador, Niagara, EV-302, and Litespark. While more study is needed to determine the best approach, having these additional options is a win for patient care. Dr. Guru shares his thoughts on these important trials and how they have shaped recent discussions in GU cancer research. Dr. Amol adds his perspective on the significance of these trials and the need for continued research. As the episode wraps up, both experts emphasize the value of ongoing collaboration and research, promising more in-depth discussions in the future. Don’t miss out on this lively exchange of insights into the latest advancements in urologic oncology! Check out clin.larvol.com for more oncology data, and don’t forget to follow Dr. Guru and Dr. Amol on social media for updates on future trials. #ESMO24 #GUOncology #AmbassadorTrial #NiagaraTrial #EV302 #Litespark #Oncology #LARVOL
32 एपिसोडस
साझा करें
